Cancer is still a big problem

Cancer is still a big problem

Cancer is still a major global health problem. In the U.S. alone, more than 600,000 people die from cancer each year, even though over $20 billion per year is spent on research.  The most advanced cancer treatments often cost more than $400,000, which is not affordable for the average person. To make things worse, the cost and time of drug development is only increasing, which means this will not be solved soon.

At Humane Genomics, we are pioneering synthetic virology to deliver personalized cancer therapies and ensure humane care.

Viruses are the most abundant biological entity on earth, and have broad utility in research and commercial applications. Some are even known to kill cancer cells, these are called oncolytic viruses. 

To make the best possible oncolytic viruses we will design them (on a computer) and then synthesize and assemble them. This will enable us to make personalized treatments, specifically engineered for each patient with maximum therapeutic effect.

Oncolytic viruses

Computer Aided Design

Personalized for each patient to effectively kill cancer

What we do

We evaluate your clinical data and use next-generation sequencing to identify unique aspects of your tumor. Next, we use our proprietary design platform and digital library to construct an oncolytic virus that is tailor-made for your cancer. We then use state-of-the-art DNA synthesis and laboratory robotics to physically build the oncolytic viruses. Finally, we test our therapies on cancer cells collected from the patient’s biopsy, so we know they are safe and work for you.

We envision a world where cancer therapies are available for everyone at an affordable price. To make this a reality, we are on a mission to build an end-to-end platform for developing synthetic viruses and manufacture these therapies at scale. We are pioneering Drug Development as a Service, completed in weeks, not years.

Our initial efforts are focused on solving cancer in dogs. After we validate our platform, we will pursue human clinical trials.